ICE方案治疗复发难治性非霍奇金弥漫大B细胞淋巴瘤临床观察  

Recurrence of ICE Regimen for Refractory Non-Hodgkin's Diffuse Large B Cell Lymphoma in Clinical Observation

作　　者：梁欢[1] 贾垂明[1] 王燕[1] 刘志强[1] 刘爱春[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代生物医学进展》2015年第2期274-276,269,共4页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅科学研究项目(1154h13)

摘　　要：目的:观察ICE方案(异环磷酰胺IFO,卡铂CBP,依托泊苷VP-16)治疗复发/难治性非霍奇金弥漫大B细胞淋巴瘤(Non-hodgkin's lymphoma,NHL)的疗效及安全性。方法:20例经系统化疗后复发或进展的非霍奇金弥漫大B细胞淋巴瘤(DLBCL)患者,采用ICE方案化疗至少2周期,IFO 5 g/m2,第2天,持续24小时静脉输注,CBP按AUC=5,max 800 mg,第2天,静脉输注,VP-16.100 mg/m2,第1-3天,静脉输注。结果:完全缓解(complete response,CR)5例,部分缓解(partial response,PR)8例,疾病稳定(stable disease,SD)4例,疾病进展(progress disease,PD)3例,总有效率(overall response rate,ORR,CR+PR)65%,化疗副作用主要为骨髓抑制(Ⅰ、Ⅱ度6例,Ⅲ、Ⅳ度14例),其他不良反应包括胃肠道反应、粘膜损伤、肝肾毒性及脱发等均可耐受。结论:ICE方案可用于非霍奇金弥漫大B细胞淋巴瘤的二线化疗方案。Objective： To evaluate the safety and efficacy of the ifosfamide （IFO） combined with carboplatin （CBP） and vepeside （VP-16） in the treatment of patients with relapsed or refractory non-Hodgkin＇s lymphoma （NHL）. Methods： Twenty patients with conformed relapsed or refractory Non-hodgkin＇s lymphoma （NHL） were enrolled in this study. The chemotheraphy of regimen consisted of IFO（5 g/m2, day 2, continue 24 h）, carboplatin（CBP=5, max 800 mg, day 2）, and vepeside（100 mg/m2, day 1-3）. Results： In the twenty cases,the complete response was in 5 cases, the partial response was in 8 cases, 4 cases was no change, 3 cases was progressive, and the oveall reponse rate （CR＋PR） was 65%. Side effect of chemotherapy mainly manifest as bone marrow suppression, while other adverse reactions, including gastrointestinal reaction, mucosal injury, liver and kidney toxicity and hair loss, can be tolerated. Conclusion： ICE regimen can achieve a safety result in the treatment of relapsed or refractory non-Hodgkin＇s lymphoma （NHL）, and the toxicity was tolerable.

关 键 词：非霍奇金弥漫大B细胞淋巴瘤 复发/难治 ICE方案 

分 类 号：R733[医药卫生—肿瘤]